PERIPHERAL TRANSCUTANEOUS NEUROMODULATION OF THE POST-TIBIAL NERVE (T-PTNS) FOR SOLIFENACIN 10mg. IN THE TREATMENT OF HYPERACTIVE BLADDER SYNDROME: NON-INFERIORITY PHASE IV RANDOMIZED CLINICAL TRIAL

Registry ID

EUCTR2017-000605-20

Source registry

EUCTR

Status

Ongoing

Phase

PHASE4

Sponsor

Fundación para la Formación e Investigación Sanitarias de la Región de Murcia

Start date

2017-07-26

Last update

2026-08-16

Conditions

• Overactive Bladder Syndrome

Summary

- To determine if the T-PTNS is not inferior in the short term (3 months) to one of the usual pharmacological treatments (Solifenacin) in the treatment of SVHI and with respect to the percentage of patients that improve 50% any of the 3 signs (Urinary frequency, diurnal / nocturnal frequency, urgency and urinary incontinence). - To determine prognostic factors associated with insufficient improvement (less than 50% in the 3 main signs of SVHI (urinary frequency, urgency and urinary incontinence frequency) after treatment with T-PTNS and Solifenacin.

Locations

• , , Spain

Related clinical trials

• Improving Overactive Bladder Treatment Access and Adherence
• BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
• Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
• Impact of TTNS on Bladder Symptoms Among People With MS, A RCT
• Moving Beyond p-Values: MCID for OAB-V8 8 and ICIQ-SF in Patients With OAB
• Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

View on source registry